Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?

• Published in: Cytotherapy (Oxford, England) Vol. 25; no. 3; pp. 341 - 352
• Main Authors: Kirkham, Aidan M., Bailey, Adrian J.M., Shorr, Risa, Lalu, Manoj M., Fergusson, Dean A., Allan, David S.
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.03.2023
• Subjects: acute respiratory distress syndrome; COVID-19; COVID-19 - therapy; extracellular vesicles; Humans; Mesenchymal Stem Cells - metabolism; mesenchymal stromal cells; MSCs; Pandemics; Randomized Controlled Trials as Topic; SARS-CoV-2; COVID-19; acute respiratory distress syndrome; MSCs; SARS-CoV-2; extracellular vesicles; mesenchymal stromal cells
• ISSN: 1465-3249; 1477-2566
• DOI: 10.1016/j.jcyt.2022.10.003

Evidence regarding the extent that mesenchymal stromal cells (MSCs) may improve clinical outcomes in patients with coronavirus disease 2019 (COVID-19) has been limited by marked inter-study heterogeneity, inconsistent product characterization and appreciable risk of bias (RoB). Given the evolution of treatment options and trajectory of the pandemic, an updated analysis of high-quality evidence from randomized controlled trials is needed for a timely and conclusive understanding of the effectiveness of MSCs. A systematic literature search through March 30, 2022, identified all English language, full-text randomized controlled trials examining the use of MSCs in the treatment of COVID-19. Eight studies were identified (316 patients, 165 administered MSCs and 151 controls). Controls evolved significantly over time with a broad range of comparison treatments. All studies reported mortality at study endpoint. Random effects meta-analysis revealed that MSCs decreased relative risk of death (risk ratio, 0.63, 95% confidence interval, 0.42–0.94, P = 0.02, I2 = 14%) with no significant difference in absolute risk of death. MSCs decreased length of hospital stay and C-reactive protein levels and increased odds of clinical improvement at study endpoint compared with controls. Rates of adverse events and severe adverse events were similar between MSC and control groups. Only two (25%) studies reported all four International Society for Cell & Gene Therapy criteria for MSC characterization. Included studies had low (n = 7) or some (n = 1) concerns regarding RoB. MSCs may reduce risk of death in patients with severe or critical COVID-19 and improve secondary clinical outcomes. Variable outcome reporting, inconsistent product characterization and variable control group treatments remain barriers to higher-quality evidence and may constrain clinical usage. A master protocol is proposed and appears necessary for accelerated translation of higher-quality evidence for future applications of MSC therapy. Forest plot demonstrating significantly decreased relative risk of death at study endpoint in patients administered MSCs (experimental) compared with patients not administered MSCs (control). Control groups received standard of care for COVID-19 at the time of hospital admission, which varied depending on the institution. [Display omitted]